Core B Medicinal Chemistry

核心 B 药物化学

基本信息

项目摘要

Abstract The Medicinal Chemistry (MedChem) Core has been formed to address the urgent need for novel antibacterial agents. The MedChem Core will work seamlessly with the Project Teams and other Cores to drive the time- and cost-efficient discovery and development of novel lead compounds to target high-threat bacterial infections. Critical to its mission are its competencies in industrial and academic medicinal chemistry, cheminformatics, and structural biology, which are complemented by decades of experiences with the fundamental biology of the relevant bacterial agents. The MedChem Core will aid in the confirmation of hits discovered through computation or experimental screens, evolve these to early and then optimized leads following a defined workflow with quantitative metrics for molecules at each stage in the process. The MedChem Core will collaborate on projects focused on the discovery and development of A) phloroglucinol and myxopyronin antibacterials, B) rifamycin and oxazolidinone agents against Mycobacterium abscessus, C) antituberculars targeting cell wall biosynthesis or respiration, D) antibiotics suggested by mining of biosynthetic gene clusters, and E) bacterial cell envelope biogenesis inhibitors to prevent Gram-negative multi-drug resistant infections.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joel Stephen Freundlich其他文献

Joel Stephen Freundlich的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joel Stephen Freundlich', 18)}}的其他基金

A Preclinical Program for Targeting Mycobacterium tuberculosis KasA
针对结核分枝杆菌 KasA 的临床前计划
  • 批准号:
    10466840
  • 财政年份:
    2021
  • 资助金额:
    $ 91.53万
  • 项目类别:
A Preclinical Program for Targeting Mycobacterium tuberculosis KasA
针对结核分枝杆菌 KasA 的临床前计划
  • 批准号:
    10209330
  • 财政年份:
    2021
  • 资助金额:
    $ 91.53万
  • 项目类别:
A Preclinical Program for Targeting Mycobacterium tuberculosis KasA
针对结核分枝杆菌 KasA 的临床前计划
  • 批准号:
    10681371
  • 财政年份:
    2021
  • 资助金额:
    $ 91.53万
  • 项目类别:
Core B Medicinal Chemistry
核心 B 药物化学
  • 批准号:
    10394986
  • 财政年份:
    2019
  • 资助金额:
    $ 91.53万
  • 项目类别:
Core B Medicinal Chemistry
核心 B 药物化学
  • 批准号:
    10613886
  • 财政年份:
    2019
  • 资助金额:
    $ 91.53万
  • 项目类别:
Bayesian models to accelerate antibacterial drug discovery
贝叶斯模型加速抗菌药物的发现
  • 批准号:
    9243961
  • 财政年份:
  • 资助金额:
    $ 91.53万
  • 项目类别:
Medicinal Chemistry Core
药物化学核心
  • 批准号:
    8655936
  • 财政年份:
  • 资助金额:
    $ 91.53万
  • 项目类别:
Bayesian models to accelerate antibacterial drug discovery
贝叶斯模型加速抗菌药物的发现
  • 批准号:
    8841308
  • 财政年份:
  • 资助金额:
    $ 91.53万
  • 项目类别:
Bayesian models to accelerate antibacterial drug discovery
贝叶斯模型加速抗菌药物的发现
  • 批准号:
    9020195
  • 财政年份:
  • 资助金额:
    $ 91.53万
  • 项目类别:
Bayesian models to accelerate antibacterial drug discovery
贝叶斯模型加速抗菌药物的发现
  • 批准号:
    8655931
  • 财政年份:
  • 资助金额:
    $ 91.53万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 91.53万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 91.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
    Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
    Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 91.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了